Synthetic Biology: Global Markets

Published - Jul 2018| Analyst - John Bergin| Code - BIO066E
Synthetic Biology: Global Markets
Single User License: $5,500 Member Price: FREE

Report Highlights

The global market for synthetic biology will grow from nearly $4.4 billion in 2017 to $13.9 billion by 2022, with a compound annual growth rate (CAGR) of 26.0% for the period of 2017-2022.

Report Includes

  • An overview of the global markets for synthetic biology
  • Analyses of global market trends, with data from 2016, 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • Coverage of core synthetic biology products: synthetic genes, other DNA parts, chassis organisms, synthetic cells
  • Coverage of enabling technologies: DNA sequencing, oligonucleotides, specialty media, bioinformatics
  • Coverage of enabled technologies: biofuels, specialty chemicals, diagnostics, pharmaceuticals, agriculture 
  • Analysis of the synthetic biology industry structure, competitors, and intellectual property landscape
  • Assessments of the products and technologies most commercially viable now and in the near future 
  • Company profiles of major players in the market, including Illumina, Inc, New England Biolabs, Precision Biosciences, Royal Dsm Nv, Sgi-Dna Inc., Synthetic and Genomics, Inc

Report Scope

The scope of this study includes core synthetic biology products (synthetic genes, BioBrick parts, delivery plasmids, chassis organisms, synthetic cells, cell-free systems and production systems), enabling technologies (DNA sequencing, DNA synthesis and assembly, gene editing, bioinformatics and specialty media) and enabled technologies (healthcare, industrial chemicals, consumer products, food and beverages, and agriculture) that are already commercialized or are forecast to be commercialized within the next five years.

We analyze key synthetic biology technologies and products to determine present and future market status and forecasted growth from 2017 through 2022. We also discuss strategic alliances, industry structures, competitive dynamics, patents, and market-driving forces.

BCC Research examines the synthetic biology industry by market segment, including the following segments: DNA sequencing, DNA synthesis, gene editing, synthetic biology foundries, software, and the following enabled products sectors: agriculture, consumer products, cosmetics/skin care, food and beverages, healthcare, and industrial chemicals.

The role of key strategic alliances and acquisitions from 2016 through 2017 is discussed. Emerging markets including synthetic genes, synthetic biology-enabled drugs and vaccines, genome-edited crops, and chassis organisms, as well as metabolically engineered factories for producing synthetic fuels and specialty chemicals are analyzed, and more than 185 companies in these fields are highlighted.

Analyst Credentials

John Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company, as well as executive management positions with a nanotechnology/separations company. Bergin holds a B.S. degree in Chemistry, an M.S. degree in Biotechnology and a Master of Business Administration. John Bergin is a pseudonym of the author.

Select reports include:

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
 
Published - Jan-2017| Analyst - John Bergin| Code - BIO066D

Report Highlights

The global synthetic-biology market reached nearly $3.9 billion in 2016 and should reach $11.4 billion by 2021, growing at a compound annual growth rate (CAGR) of 24.0% through 2021.

Report Includes

  • An overview of the global markets for synthetic biology.
  • Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.
  • Coverage of core synthetic biology products: synthetic genes, other DNA parts, chassis organisms, synthetic cells
  • Coverage of enabling technologies: DNA sequencing, oligonucleotides, specialty media, bioinformatics
  • Coverage of enabled technologies: biofuels, specialty chemicals, diagnostics, pharmaceuticals, agriculture 
  • Analysis of the synthetic biology industry structure, competitors and intellectual property landscape
  • An assessment of the products and technologies most commercially viable in the immediate and near-future time frame.
  • Profiles of major players in the industry
Published - Jun-2014| Analyst - John Bergin| Code - BIO066C

Report Highlights

The global synthetic biology market reached nearly $2.1 billion in 2012 and $2.7 billion in 2013. This market is expected to grow to $11.8 billion in 2018 with a compound annual growth rate (CAGR) of 34.4% over the five-year period from 2013 to 2018.

Report Includes

  • An overview of the global market for synthetic biology.
  • Analyses of global market trends, with data from 2012 and 2013, and projections of compound annual growth rates (CAGRs) through 2018.
  • Information on the applications for synthetic biology including specialty chemicals, enzymes, synthetic genes and other DNA parts, pharmaceuticals, biofuels, and chassis microorganisms.
  • An assessment of the products and technologies most commercially viable in the immediate and near-future time frame.
  • Comprehensive profiles of leading companies in the industry.
Published - Nov-2011| Analyst - John Bergin| Code - BIO066B

Report Highlights

The global value of the synthetic biology market reached $1.1 billion in 2010. It is expected to reach $1.6 billion in 2011 and it will further grow to $10.8 billion by 2016, increasing at a compound annual growth rate (CAGR) of 45.8.%.

Published - Jun-2009| Analyst - John Bergin| Code - BIO066A

Report Highlights

  • The global market for synthetic biology generated $233.8 million in 2008. This is expected to increase to $2.4 billion in 2013, for a compound annual growth rate (CAGR) of 59.8%.
  • The chemicals and energy segment has the largest share of the market, worth $80.6 million in 2008. This should reach $1.6 billion in 2013, for a CAGR of 81.6%.
  • The biotechnology and pharmaceuticals segment is the second-largest market segment, worth 80.3 million in 2008. This segment is projected to increase at a CAGR of 49.2% to reach $594 million in 2013.
Want to Customize this Report?

Contact us for a confidential discussion.

781-205-2433

Custom Report
RELATED REPORTS
Share This Report